Table 1—

Baseline characteristics

PlaceboCLAt10c12 CLA
n191919
Age (years)53 ± 10.151 ± 7.155 ± 7.1
Heredity for diabetes (%)8.810.57.0
Antihypertensive therapy (%)9.07.26.1
Weight (kg)97.8 ± 10.098.3 ± 10.1100.2 ± 12.0
BMI (kg/m2)30.2 ± 1.830.1 ± 1.831.2 ± 2.5
Waist-to-hip ratio1.01 ± 0.031.01 ± 0.021.01 ± 0.03
Waist girth (cm)112.2 ± 5.0112.5 ± 7.1116.0 ± 9.6
SAD (cm)28.2 ± 1.828.2 ± 1.928.9 ± 2.3
Body fat (%)35.3 ± 4.636.4 ± 4.436.7 ± 3.0
Lean body mass (kg)61.9 ± 6.961.1 ± 6.061.9 ± 7.3
Insulin sensitivity (M) (mg · kg−1 · min)3.7 ± 1.6*4.5 ± 1.53.9 ± 1.5
Plasma insulin (pmol/l)73.2 ± 3064.8 ± 23.468.4 ± 26.4
Plasma glucose (mmol/l)5.7 ± 0.65.9 ± 0.75.6 ± 0.6
HbAlc (%)4.4 ± 0.44.4 ± 0.44.4 ± 0.3
Serum cholesterol (mmol/l)5.8 ± 1.25.5 ± 0.86.0 ± 1.3
LDL cholesterol (mmol/l)4.0 ± 0.93.8 ± 0.74.0 ± 1.1
HDL cholesterol (mmol/l)1.0 ± 0.11.0 ± 0.21.0 ± 0.1
VLDL triglycerides (mmol/l)1.5 ± 0.91.2 ± 0.41.9 ± 2.1
Serum TG (mmol/l)2.0 ± 1.01.7 ± 0.52.4 ± 2.2
Serum FFAs (mmol/l)0.56 ± 0.160.55 ± 0.180.61 ± 0.18
Serum free glycerol (mmol/l)0.120 ± 0.020.122 ± 0.020.131 ± 0.03
Serum leptin (ng/ml)10.4 ± 4.613.2 ± 10.211.6 ± 5.6
  • Data are means ± SD unless noted otherwise. There were no significant differences between the groups (ANOVA).

  • *

    * n = 18 in the placebo group.